Morgan Stanley 22nd Annual Global Healthcare Conference
Logotype for Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Zimmer Biomet Holdings Inc

Morgan Stanley 22nd Annual Global Healthcare Conference summary

30 Jun, 2026

Business performance and growth outlook

  • Achieved consistent mid-single-digit revenue growth and double-digit EPS growth over the past 10 quarters, with a strong product pipeline and operational improvements since 2018.

  • 2024 growth remains robust, with Q2 showing 5.6% revenue growth and 10% EPS growth, despite recent challenges.

  • Committed to mid-single-digit revenue growth, EPS growing 1.5x faster, and free cash flow at least 100 basis points above EPS through 2027.

  • SET and Recon (hips and knees) businesses are expected to maintain strong growth, with new product launches and increased market penetration.

  • ASC (ambulatory surgical centers) segment is a major growth driver, with 40%-60% of cases shifting to this setting and a comprehensive portfolio now in place.

ERP implementation and financial impact

  • Migration from legacy ERP to SAP in July led to operational challenges, primarily affecting the U.S. and Canada, with the 'other' business category most impacted.

  • The ERP issue could impact up to 1% of annual sales in 2024, but mitigation plans are in place to limit EPS impact and protect critical investments.

  • Confident the ERP challenges will be resolved within 2024, with service levels expected to normalize by year-end.

  • No impact anticipated for 2025 and beyond, with robust growth still expected in core business areas.

Product innovation and market positioning

  • Launching 50 new products over the next 30-36 months, including Oxford Partial Cementless knee (U.S. launch by summer 2025) and Persona IQ short stem.

  • Regaining hip market share with new products (direct anterior stem, surgical impactors, navigation) and revised sales incentives.

  • Cementless and robotic knee penetration targeted to reach 50% by 2027, with current rollouts showing strong momentum.

  • ROSA Shoulder robot is a unique competitive advantage, with U.S. and European launches planned and strong clinical trial results.

  • Robotics, navigation, and mixed reality form a comprehensive digital strategy, with optionality for different customer needs and ongoing investments in AI and non-robotic platforms.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more